

Sun Pharma posts net profit of ₹1,391 crore



BS REPORTER
Mumbai,
12 August

Sun Pharmaceuticals, India's largest drug maker by market value, has posted a net profit of ₹1,391 crore in the first quarter of FY15, compared with a net loss of ₹1,276 in the year-ago period. Net sales for the June 2014 quarter stood at ₹3,927 crore, a growth of 13 per cent over same quarter last year. The loss in the June 2013 quarter was on account of a provision of ₹2,517 crore

towards settlement for patent infringement litigation related to generic versions of 'Protonix', the company said in a statement.

The performance was pushed by the better sale of branded prescription formulations in India at ₹992 crore, up 17 per cent from the first quarter of FY14.

Sun Pharma is ranked second in India and holds a 5.4 per cent market share in the ₹77,000-crore pharma market. On Tuesday, Sun Pharma shares were closed at ₹783.9 apiece.

loss of ₹944 crore y-o-y.

BHEL profit down



State-run BHEL's net profit shrunk to ₹193.50 crore for the quarter ended June 30,

mainly due to drop in sales from power and industry segments. The company had reported a net profit of ₹465.43 crore during the same period the last financial year, BHEL said. The company's income from operations was down to ₹5,067.59 crore from ₹6,352.55 crore in the corresponding quarter the previous financial year. BHEL's revenues from power sector plummeted to ₹4,144.16 crore from ₹5,378.60 crore.

Company